FDA advisors unanimously reject Intarcia’s embattled type 2 diabetes treatmentnews2023-09-22T15:30:59+00:00September 22nd, 2023|Endpoints News|
Dana-Farber, Brigham breakup could lead to a ripple effect for CGT clinical trials for cancernews2023-09-22T15:25:04+00:00September 22nd, 2023|Endpoints News|
NYC biotech LB Pharmaceuticals eyes $75M for new take on decades-old schizophrenia drugnews2023-09-22T15:01:07+00:00September 22nd, 2023|Endpoints News|
Padcev, Keytruda’s new survival data; Seraxis raises $10M for diabetes cell therapynews2023-09-22T14:55:06+00:00September 22nd, 2023|Endpoints News|
Abpro merges with Atlantic Coastal Acquisition Corp in SPAC deal, spotlights HER2 bispecific antibodynews2023-09-22T11:05:58+00:00September 22nd, 2023|Endpoints News|
Glenmark Pharmaceuticals divests 75% stake in its API manufacturing subsidiarynews2023-09-22T11:04:46+00:00September 22nd, 2023|Endpoints News|
AstraZeneca, Daiichi Sankyo eye first approval for TROP2 drug after PhIII breast cancer successnews2023-09-22T10:21:24+00:00September 22nd, 2023|Endpoints News|
Mark Velleca takes over at Black Diamond; Verve Therapeutics separates CMO, CSO postsnews2023-09-22T10:00:21+00:00September 22nd, 2023|Endpoints News|
Roche scrutinized by UK watchdog over ‘misleading’ Rozlytrek promotional websitenews2023-09-21T19:07:46+00:00September 21st, 2023|Endpoints News|
GE HealthCare hits the road in a health tech bus to bring its latest solutions to hospital doorstepsnews2023-09-21T18:43:26+00:00September 21st, 2023|Endpoints News|
